{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T07:05:28Z","timestamp":1697612728983},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,6,12]],"date-time":"2007-06-12T00:00:00Z","timestamp":1181606400000},"content-version":"vor","delay-in-days":1684,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Congestive Heart Failure"],"published-print":{"date-parts":[[2002,11]]},"abstract":"<jats:p> <jats:italic>Angiotensin II receptor blockers (ARBs) have been available in the United States since 1995. These agents have demonstrated antihypertensive efficacy at least similar to that of agents from other antihypertensive classes. Recent large\u2010scale, randomized, controlled clinical trials have demonstrated that ARBs offer cardiovascular and renal protective benefits independent of their effects on systemic blood pressure (BP), which make them valuable as first\u2010line antihypertensive agents, especially in high\u2010risk patients. However, as is the case with other antihypertensive classes, monotherapy with the first\u2010available ARBs (losartan potassium, valsartan, and irbesartan) may not provide sufficient BP reduction to achieve currently recommended BP goals in many patients. The diuretic hydrochlorothiazide is frequently added to enhance the ability of ARBs to lower BP. Several head\u2010to\u2010head comparison studies have shown differences in antihypertensive efficacy among the available ARBs. The newest ARB, olmesartan medoxomil, was recently compared with losartan potassium, irbesartan, and valsartan in a prospective, head\u2010to\u2010head, randomized trial. In this study, olmesartan medoxomil demonstrated a significantly greater reduction in diastolic BP, the primary end point, compared with the other three ARBs. Further, a review of the absolute reductions in diastolic BP achieved with olmesartan medoxomil monotherapy appears comparable to that of previously available ARBs when they are used in combination with hydrochlorothiazide. These comparisons may have important clinical implications regarding the optimal choice of first\u2010line antihypertensive therapy.<\/jats:italic> <\/jats:p>","DOI":"10.1111\/j.1527-5299.2002.02077.x","type":"journal-article","created":{"date-parts":[[2007,6,12]],"date-time":"2007-06-12T11:20:18Z","timestamp":1181647218000},"page":"313-320","source":"Crossref","is-referenced-by-count":11,"title":["A Review of Olmesartan Medoxomil Monotherapy: Antihypertensive Efficacy Similar to That of Other Angiotensin II Receptor Blocker\/Hydrochlorothiazide Combinations?"],"prefix":"10.1111","volume":"8","author":[{"given":"Mark","family":"Greathouse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440420033005"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.1.199"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2000.16225"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.25.3.305"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010273"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812313392701"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.155.16.1757"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.4.1085"},{"key":"e_1_2_6_10_2","first-page":"41","article-title":"Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data","volume":"160","author":"Caro JJ","year":"1999","journal-title":"CMAJ"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000637"},{"issue":"12","key":"e_1_2_6_12_2","first-page":"S278","article-title":"Comparative antihypertensive effects of angiotensin II receptor antagonists","volume":"10","author":"Burnier M","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200106001-00007"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001395"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200106001-00006"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199917070-00002"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271003"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08089-3"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08090-X"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2000.048"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80212-8"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2001.01136.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200203000-00005"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80072-2"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(01)02201-4"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)00237-X"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2001.00826.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00491-3"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/080370501750275857"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)01510-7"},{"issue":"2","key":"e_1_2_6_35_2","first-page":"S155","article-title":"A multi\u2010centre, double\u2010blind, efficacy tolerability and safety study of the oral angiotensin II\u2010antagonist olmesartan medoxomil versus losartan in patients with mild to moderate essential hypertension","volume":"19","author":"Ball K","year":"2001","journal-title":"J Hypertens"},{"key":"e_1_2_6_36_2","first-page":"253","article-title":"Angiotensin II antagonists in the treatment of hypertension: more similarities than differences","volume":"2","author":"Conlin PR","year":"2000","journal-title":"J Clin Hypertens"}],"container-title":["Congestive Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1527-5299.2002.02077.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1527-5299.2002.02077.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T16:38:19Z","timestamp":1697560699000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1527-5299.2002.02077.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["10.1111\/j.1527-5299.2002.02077.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1527-5299.2002.02077.x","archive":["Portico"],"relation":{},"ISSN":["1527-5299","1751-7133"],"issn-type":[{"value":"1527-5299","type":"print"},{"value":"1751-7133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}